pSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis. The company is also developing Durasert, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. It is also developing Durasert, which is in pre-clinical trials for the treatment of posterior segment uveitis; steroid implant for severe knee osteoarthritis; and TKI Insert, an injectable, bioerodible, sustained-release Durasert insert delivering a tyrosine kinase inhibitor for treatment of wet age-related macular degeneration. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; Enigma Therapeutics Limited; and Nicox S.A. pSivida Corp. was founded in 1987 and is based in Watertown, Massachusetts.